HMGN1 loss sensitizes lung cancer cells to chemotherapy
Article in Scientific Reports (May 2024)
The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.
High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study
Article in Frontiers in Oncology (April 2024)
HMGN1 is a potential chemotherapeutic target for lung adenocarcinoma.
Preprint in Research Square (December 2023)